• Petscribers

  Led · Seed · Aug 2025

  Petscribers offers a fully integrated e-prescribing platform that lets pet owners compare medication prices from government‑approved pharmacies and streamlines the veterinary prescription process. The business was founded by qualified vets Dr Angela Jones and Dr Emma Pemberthy out of frustration with the existing system of animal care. The platform is accessible at petscribers.co.uk and aims to improve access to veterinary care. Petscribers recently completed a pre-seed raise and plans to use funds to accelerate product development and go-to-market activities. Management says there is a clear path to net profitability as the company scales. The company is based in Wiltshire in the South West of England.

• SMASH

  Participated · Seed · Mar 2024

  My SMASH Media is a disruptive AI matchmaking platform that connects content creators (for example, scriptwriters) with buyers such as streaming services, production companies and broadcasters. The platform combines sector knowledge with AI to anticipate industry trends and offers free-to-access digital tools that help creators create powerful pitches. The company has secured over £370K of investment and grants to date and is nearing a £500K fundraise. SMASH will use the funding to develop AI SMASHCupid, a more sophisticated AI matchmaking capability intended to grow user numbers and revenues by enabling buyers to reach beyond their existing networks. The company currently focuses on film and TV but plans to expand its technology into games, podcasts and video sectors. The founding team includes Fiona Gillies, Christine Hartland and Mahesh Ramachandra; SMASH has partnered with industry veteran Hilary Davis and is backed by London-based accelerator Activate Media.

• Carcinotech

  Participated · Equity · Jan 2024

  Carcinotech’s core product, Carcino3D, enables manufacture of 3D‑printed micro‑tumors using cells derived from patient biopsies and blood samples to precisely simulate the tumor microenvironment and accelerate ethical drug screening. The company positions the technology to improve delivery of more effective, personalized cancer treatments and to support oncology drug development. Carcinotech works with global partners including leading pharma companies, surgeons, pathologists and clinicians as part of its commercialization strategy. In October the company announced a partnership with CELLINK to combine CELLINK’s bioprinting solutions with Carcinotech’s expertise in producing bioprinted living tumors. Carcinotech has built traction across the UK and Europe and plans US expansion later this year. The company has strengthened its board, which is chaired by Albert Nicholl, and launched a scientific advisory board last year with world‑renowned oncology leaders.

• Cumulus Oncology

  Participated · Equity · Jul 2020

  Cumulus Oncology is an Edinburgh, Scotland oncology biotech that sources novel oncology assets from academic institutes, commercial drug discovery groups and biopharmaceutical companies. Led by founder and CEO Clare Wareing, the company identifies targets, performs due diligence and market assessment, then spins selected assets into newly created companies which it funds and manages to key development milestones. It uses AI and machine learning platforms to prioritise targets and assets and contributes early-stage capital and oncology drug development expertise to its portfolio companies. Cumulus raised £9M in a Seed financing led by Eos Advisory and the Scottish National Investment Bank to execute growth plans, expand its portfolio and accelerate development toward clinical proof of concept. Its first spinout, Nodus Oncology, is engaged in two oncology drug discovery programmes in the area of DNA damage response, and a second stealth company is slated to be unveiled in early 2024. Further projects are poised to read out important data points that will form the basis of at least a third new company creation within the next 12 months, and venture capital partners are important collaborators when spinouts reach key inflection points. Cumulus Oncology is Europe’s first oncology biotech creation company that identifies novel oncology assets to de‑risk and form spin‑out companies to commercialise cancer therapies. Founded in 2017 and based in Edinburgh, Scotland, Cumulus has created spin‑outs including Nodus Oncology (April 2020) focusing on DNA damage response and Modulus Oncology (September 2020) formed with the University of Sheffield. The company is led by CEO and co‑founder Clare Wareing. Cumulus plans to accelerate its business model to identify and develop treatments targeting unmet needs in specific cancer patient populations. It has secured a £4.1 million ($5.6 million) investment led by Eos Advisory with Scottish Enterprise participating, and an additional £1.5 million ($2.0 million) is expected to follow. Dr Russell Greig has joined the board as Chairman to help guide strategic focus, drawing on his drug development and business development experience at GlaxoSmithKline and advisory roles across biotech and VC. Cumulus Oncology is described as Europe’s first oncology drug-discovery accelerator, creating spin-out companies that develop cancer therapies. Founded in 2017, the firm focuses on fast-tracking treatments into clinical trials for cancer types that respond poorly to existing procedures. The company says it has spent three years curating a high-calibre team and building a portfolio of oncology asset-centric spin-outs. Clare Wareing, founder and CEO, has roughly 20 years’ experience with big pharma, biotech and clinical research organisations and previously founded Nexus Oncology, which was acquired by Ockham in 2012. Cumulus aims to scale its business model across Europe and capitalise on what it describes as significant market opportunities. The team positions itself to attract venture capital and trade investors as European biotech investment grows.

No current team members are available.